148 related articles for article (PubMed ID: 17348833)
81. New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents.
Carballeira NM
Prog Lipid Res; 2008 Jan; 47(1):50-61. PubMed ID: 18023422
[TBL] [Abstract][Full Text] [Related]
82. The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.
Marreddy RKR; Wu X; Sapkota M; Prior AM; Jones JA; Sun D; Hevener KE; Hurdle JG
ACS Infect Dis; 2019 Feb; 5(2):208-217. PubMed ID: 30501172
[TBL] [Abstract][Full Text] [Related]
83. Targeting Mycobacterium Tuberculosis Enoyl-Acyl Carrier Protein Reductase Using Computational Tools for Identification of Potential Inhibitor and their Biological Activity.
Kuldeep J; Sharma SK; Sharma T; Singh BN; Siddiqi MI
Mol Inform; 2021 May; 40(5):e2000211. PubMed ID: 33283460
[TBL] [Abstract][Full Text] [Related]
84. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
Muench SP; Stec J; Zhou Y; Afanador GA; McPhillie MJ; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Prigge ST; Rice DW; McLeod R
Bioorg Med Chem Lett; 2013 Jun; 23(12):3551-5. PubMed ID: 23664871
[TBL] [Abstract][Full Text] [Related]
85. Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
Cheng G; Muench SP; Zhou Y; Afanador GA; Mui EJ; Fomovska A; Lai BS; Prigge ST; Woods S; Roberts CW; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Rice DW; McLeod R
Bioorg Med Chem Lett; 2013 Apr; 23(7):2035-43. PubMed ID: 23453069
[TBL] [Abstract][Full Text] [Related]
86. Enzyme Mechanism and Slow-Onset Inhibition of Plasmodium falciparum Enoyl-Acyl Carrier Protein Reductase by an Inorganic Complex.
de Medeiros PS; Ducati RG; Basso LA; Santos DS; da Silva LH
Enzyme Res; 2011; 2011():642758. PubMed ID: 21603269
[TBL] [Abstract][Full Text] [Related]
87. Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.
Hirschbeck MW; Kuper J; Lu H; Liu N; Neckles C; Shah S; Wagner S; Sotriffer CA; Tonge PJ; Kisker C
Structure; 2012 Jan; 20(1):89-100. PubMed ID: 22244758
[TBL] [Abstract][Full Text] [Related]
88. Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).
Hevener KE; Santarsiero BD; Lee H; Jones JA; Boci T; Johnson ME; Mehboob S
Acta Crystallogr F Struct Biol Commun; 2018 Feb; 74(Pt 2):105-112. PubMed ID: 29400320
[TBL] [Abstract][Full Text] [Related]
89. Novel compounds targeting InhA for TB therapy.
AlMatar M; Makky EA; Var I; Kayar B; Köksal F
Pharmacol Rep; 2018 Apr; 70(2):217-226. PubMed ID: 29475004
[TBL] [Abstract][Full Text] [Related]
90. Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis.
Hevener KE; Mehboob S; Boci T; Truong K; Santarsiero BD; Johnson ME
Protein Expr Purif; 2012 Sep; 85(1):100-8. PubMed ID: 22820244
[TBL] [Abstract][Full Text] [Related]
91. Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in
Singh K; Pandey N; Ahmad F; Upadhyay TK; Islam MH; Alshammari N; Saeed M; Al-Keridis LA; Sharma R
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009907
[No Abstract] [Full Text] [Related]
92. Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora.
Shilpi JA; Ali MT; Saha S; Hasan S; Gray AI; Seidel V
In Silico Pharmacol; 2015 Dec; 3(1):10. PubMed ID: 26820895
[TBL] [Abstract][Full Text] [Related]
93. Development of 1,2,4-Triazole-5-Thione Derivatives as Potential Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) in Tuberculosis.
Vora D; Upadhyay N; Tilekar K; Jain V; Ramaa CS
Iran J Pharm Res; 2019; 18(4):1742-1758. PubMed ID: 32184843
[TBL] [Abstract][Full Text] [Related]
94. Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide-Hydrazone and Thiadiazole Derivatives Targeting InhA.
Teneva Y; Simeonova R; Valcheva V; Angelova VT
Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111241
[TBL] [Abstract][Full Text] [Related]
95. Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors.
Albelwi FF; Abdu Mansour HM; Elshatanofy MM; El Kilany Y; Kandeel K; Elwakil BH; Hagar M; Aouad MR; El Ashry ESH; Rezki N; El Sawy MA
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890098
[TBL] [Abstract][Full Text] [Related]
96. Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity.
Dixit SR; Joshi SD; Kulkarni VH; Jalalpure SS; Kumbar VM; Mudaraddi TY; Nadagouda MN; Aminabhavi TM
Open Med Chem J; 2017; 11():92-108. PubMed ID: 29151986
[TBL] [Abstract][Full Text] [Related]
97.
Dingiş Birgül Sİ; Kumari J; Tamhaev R; Mourey L; Lherbet C; Sriram D; Akdemir A; Küçükgüzel İ
J Biomol Struct Dyn; 2024 Mar; ():1-19. PubMed ID: 38450660
[TBL] [Abstract][Full Text] [Related]
98. Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
Fernández de Luco J; Recio-Balsells AI; Ghiano DG; Bortolotti A; Belardinelli JM; Liu N; Hoffmann P; Lherbet C; Tonge PJ; Tekwani B; Morbidoni HR; Labadie GR
RSC Med Chem; 2021 Jan; 12(1):120-128. PubMed ID: 34046604
[TBL] [Abstract][Full Text] [Related]
99. Chorismate synthase: an attractive target for drug development against orphan diseases.
Dias MV; Ely F; Palma MS; de Azevedo WF; Basso LA; Santos DS
Curr Drug Targets; 2007 Mar; 8(3):437-44. PubMed ID: 17348836
[TBL] [Abstract][Full Text] [Related]
100. Navigating the Chemical Space of ENR Inhibitors: A Comprehensive Analysis.
Kuralt V; Frlan R
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
